Close Menu

NEW YORK – Oncocyte said on Thursday that it is collaborating with the Fondazione Michelangelo in Milan, Italy to evaluate the company's DetermaIO test as a therapy response predictor in the NeoTRIPaPDL1 trial.

DetermaIO is a tissue-based gene expression assay, designed to evaluate signals associated with the tumor immune microenvironment. The test stratifies patients according to their likelihood of responding to immunotherapy.

To read the full story....

...and receive Weekly News bulletins.

Already have a Precision Oncology News or 360Dx or GenomeWeb account?
Login Now.

Don't have a Precision Oncology News or 360Dx or GenomeWeb account?
Register for Free.